hI Werds,
the current short term FDA opportunity is worth circa NZD$25- 27 million in sales (1 million tins) and $5-6 million in profit( less any extra over overheads). Not a game changer by any means.
the big kicker is if FDA grants permanent access and A2 would be able to sell IF ongoing, you could see this growing to 5 million tins a year business i.e NZD$125-150 million sales and $25-30 million in profit.
Ann: Deferral of FDA consideration of enforcement discretion, page-100
Add A2M (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$6.92 |
Change
-0.095(1.36%) |
Mkt cap ! $5.020B | |||
| Open | High | Low | Value | Volume |
| $6.99 | $7.02 | $6.91 | $8.763M | 1.258M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 17440 | $6.91 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.92 | 22115 | 26 |
View Market Depth
| Last trade - 15.25pm 30/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$6.90 |
Change
-0.095 ( 1.39 %) |
||||
| Open | High | Low | Volume | ||
| $7.00 | $7.03 | $6.90 | 714179 | ||
| Last updated 15.45pm 30/05/2024 ? | |||||
| A2M (ASX) Chart |